Wednesday, June 10, 2026
🇺🇸 FDA

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs — 642 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Anaxis Pharma projects

642 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 642 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

642 programs

Clinical programs

Page 11 of 14

  1. Bioequivalence of Cladribine 10 mg from two different products

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers. The intended indication is for treatment of adult patients with highly active relapsing multiple sclerosis (MS).

    phase 1 other active

    1 trial

  2. Bioequivalence study of GP-IMP-001 with regards to reference product

    Lacuna Pharma Pty Ltd

    healthy volunteers

    phase 1 other active

    1 trial

  3. CHE24001

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  4. CIM24001

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  5. CL1-210-03

    Lacuna Pharma Pty Ltd

    Cardiac arrhythmias

    phase 1 other active

    1 trial

  6. CLARI-21-24

    Lacuna Pharma Pty Ltd

    Infectious diseases

    phase 1 other active

    1 trial

  7. COR1167-101

    Lacuna Pharma Pty Ltd

    Chronic heart failure

    phase 1 other active

    1 trial

  8. COR1167-102

    Lacuna Pharma Pty Ltd

    Chronic Heart Failure

    phase 1 other active

    1 trial

  9. COR1389-101

    Lacuna Pharma Pty Ltd

    Obesity / Right heart failure (healthy participants)

    phase 1 other active

    1 trial

  10. CP543.1017

    Lacuna Pharma Pty Ltd

    alopecia areata

    phase 1 other active

    1 trial

  11. CPA 560-24

    Lacuna Pharma Pty Ltd

    influenza

    phase 1 other active

    1 trial

  12. CPO25001

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  13. CSO24001

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  14. CX842A2104

    Lacuna Pharma Pty Ltd

    Erosive Gastroesophageal Reflux Disease (eGERD)

    phase 1 other active

    1 trial

  15. CX842B2111

    Lacuna Pharma Pty Ltd

    Helicobacter pylori infection, GERD

    phase 1 other active

    1 trial

  16. Ceftobiprole OATP1B interaction study

    Lacuna Pharma Pty Ltd

    Community-acquired bacterial pneumonia

    phase 1 other active

    1 trial

  17. DBP-053-01

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 1 other active

    1 trial

  18. DEADA-07-23

    Lacuna Pharma Pty Ltd

    ADHD

    phase 1 other active

    1 trial

  19. DEUCR-07-25

    Lacuna Pharma Pty Ltd

    plaque psoriasis

    phase 1 other active

    1 trial

  20. DEUCR-08-25

    Lacuna Pharma Pty Ltd

    plaque psoriasis

    phase 1 other active

    1 trial

  21. DMT in healthy subjects

    Lacuna Pharma Pty Ltd

    Stroke

    phase 1 other active

    1 trial

  22. DPH001-01

    Lacuna Pharma Pty Ltd

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  23. DPH001-01

    Lacuna Pharma Pty Ltd

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  24. DV0012

    Lacuna Pharma Pty Ltd

    Healthy Volunteers

    phase 1 other active

    1 trial

  25. EMPAG-05-24

    Lacuna Pharma Pty Ltd

    Diabetes

    phase 1 other active

    1 trial

  26. ENZAL-15-24

    Lacuna Pharma Pty Ltd

    Prostate cancer

    phase 1 other active

    1 trial

  27. ENZAL-16-24

    Lacuna Pharma Pty Ltd

    Prostate cancer

    phase 1 other active

    1 trial

  28. EP-262-102

    Lacuna Pharma Pty Ltd

    Chronic Inducible Urticaria

    phase 1 other active

    1 trial

  29. EP395-006

    Lacuna Pharma Pty Ltd

    Healthy volunteers [targeted indication: chronic obstructive pulmonary disease (COPD)]

    phase 1 other active

    1 trial

  30. EWO-ISO-2024/BE2

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence study)

    phase 1 other active

    1 trial

  31. EYP001-110/OP1147

    Lacuna Pharma Pty Ltd

    Healthy volunteers, Impaired renal function and suspected MASH

    phase 1 other active

    1 trial

  32. Evaluation of AG-181 in Subjects 18 to 69 Years of Age With Phenylketonuria

    Lacuna Pharma Pty Ltd

    Phenylketonuria

    phase 1 other active

    1 trial

  33. Evaluation of bioequivalence of two products...

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  34. EyeD-010-003

    Lacuna Pharma Pty Ltd

    Glaucoma

    phase 1 other active

    1 trial

  35. FPI-2505-001

    Lacuna Pharma Pty Ltd

    small cell lung cancer, non-smallcell lung cancer, colorectal cancer, breast cancer, Pancreatic cancer and gastric cancer

    phase 1 other active

    1 trial

  36. FS120-19101

    Lacuna Pharma Pty Ltd

    Advanced Malignancies

    phase 1 other active

    1 trial

  37. FS222-19101

    Lacuna Pharma Pty Ltd

    Advanced Malignancies

    phase 1 other active

    1 trial

  38. G23-00

    Lacuna Pharma Pty Ltd

    healthy volunteer

    phase 1 other active

    1 trial

  39. GBP-NIB1-101

    Lacuna Pharma Pty Ltd

    rheumatoid arthritis

    phase 1 other active

    1 trial

  40. GL-ULI-1001

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  41. GL-ULI-1001

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  42. GZR33-T1D-US101

    Lacuna Pharma Pty Ltd

    Type 1 diabetes Mellitus

    phase 1 other active

    1 trial

  43. HDP-102-01

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-cell Malignancies

    phase 1 other active

    1 trial

  44. HS-10296-108

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations, Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations

    phase 1 other active

    1 trial

  45. HS135-002

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 1 other active

    1 trial

  46. HS235-002

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 1 other active

    1 trial

  47. HV-APL-A-001-24

    Lacuna Pharma Pty Ltd

    Virus diseases

    phase 1 other active

    1 trial

  48. ID-080-111

    Lacuna Pharma Pty Ltd

    Not applicable - healthy volunteer trial

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

642 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.